Tempus AI (NASDAQ:TEM) Trading Up 5.3% – What’s Next?

Shares of Tempus AI, Inc. (NASDAQ:TEM) rose 5.3% during trading on Monday . The stock traded as high as $59.80 and last traded at $60.40. Approximately 6,700,130 shares traded hands during mid-day trading, a decline of 34% from the average daily volume of 10,095,790 shares. The stock had previously closed at $57.39.

Analyst Upgrades and Downgrades

TEM has been the subject of several analyst reports. TD Cowen reaffirmed a “buy” rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research note on Wednesday. Piper Sandler reaffirmed a “neutral” rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Wolfe Research assumed coverage on Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Loop Capital dropped their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Finally, Guggenheim initiated coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Stock Performance

The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm has a fifty day moving average price of $44.20 and a 200-day moving average price of $48.58.

Insider Transactions at Tempus AI

In other Tempus AI news, Director David R. Epstein sold 620 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares in the company, valued at $1,166,248.14. The trade was a 2.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the sale, the chief accounting officer now directly owns 57,237 shares of the company’s stock, valued at $3,434,220. The trade was a 19.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,037,702 shares of company stock worth $89,449,651 in the last three months.

Institutional Trading of Tempus AI

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC purchased a new position in Tempus AI in the 2nd quarter worth approximately $633,000. Millennium Management LLC bought a new position in shares of Tempus AI during the second quarter worth about $8,067,000. The Manufacturers Life Insurance Company acquired a new position in Tempus AI in the second quarter worth about $946,000. Carnegie Investment Counsel bought a new stake in Tempus AI in the third quarter valued at about $7,936,000. Finally, Exchange Traded Concepts LLC acquired a new stake in Tempus AI during the third quarter valued at approximately $3,458,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.